
Solstice beats estimates in first post-spin earnings, initiates dividend
Solstice Advanced Materials (NASDAQ:SOLS) signaled a strong start to its life as an independent company, reporting fourth-quarter revenue that topped $987 million and declaring its first-ever quarterly dividend.
The Morris Plains, New Jersey-based specialty materials leader, which completed its spinoff from Honeywell International in late 2025, saw net sales climb 8% year-over-year.
The growth was driven by a surge in its "alternative energy services" segment, specifically nuclear materials, alongside robust demand for electronic materials and its signature low-global-warming-potential (LGWP) refrigerants.
The company’s Metropolis Works facility—the only domestic uranium hexafluoride conversion site in the U.S.—is proving to be a crown jewel.
Just yesterday, Solstice announced an expansion at the facility to meet a $2 billion backlog, aiming to increase production by 20% by 2026.
"Our strong fourth-quarter results reinforce the value of our differentiated technology platform," said CEO David Sewell.
"We are seeing continued momentum in businesses aligned with key secular growth trends, such as data centers, AI, and nuclear energy."
For the full year 2025, Solstice generated $3.9 billion in net sales and a net income of $237 million.
Despite a slight dip in adjusted EBITDA margins to 19.1% in the quarter—largely due to one-time separation costs and a shift in product mix—the company provided upbeat guidance for 2026.
It expects net sales to reach up to $4.1 billion, supported by the ongoing transition to environmentally friendly cooling solutions and the expansion of the domestic nuclear supply chain.
Reflecting management's confidence, the Board of Directors declared a quarterly dividend of $0.075 per share, payable on March 10, 2026.
More from United States
Amazon Q3 revenue accelerates 12% to $201.9 billion as AWS growth accelerates
Intel Q3 revenue skyrockets 21% to $16.5B as data center sales surge
Merck raises FY profit outlook as Q3 revenue climbs 5% to $18.1B
Eli Lilly Q3 revenue surges 39% to $24.4 billion as guidance rises
Enterprise Products Q3 EBITDA jumps 16% to $2.8 billion
KBR Q3 revenue rises 5% to $2 billion as adjusted EBITDA grows 12%